Literature DB >> 23649990

Ceftaroline-induced eosinophilic pneumonia.

Kunal R Desai1, Steven D Burdette, Hari M Polenakovik, Jared Hagaman, Craig M Pleiman.   

Abstract

We present a case of eosinophilic pneumonia due to ceftaroline used for the treatment of methicillin-resistant Staphylococcus aureus bacteremia associated with a postoperative spinal infection. Our patient developed shortness of breath and hypoxemia on the fifth week of ceftaroline therapy. Chest imaging disclosed diffuse bilateral infiltrates. Laboratory abnormalities included peripheral eosinophilia and eosinophilic predominant bronchoalveolar lavage fluid. The combination of ceftaroline discontinuation plus initiation of steroid treatment resulted in complete resolution of signs, symptoms, and radiologic abnormalities. We speculate about possible mechanisms underlying this adverse event and diagnostic criteria for drug-induced eosinophilic pneumonia.
© 2013 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  adverse event; ceftaroline; eosinophilic pneumonia

Mesh:

Substances:

Year:  2013        PMID: 23649990     DOI: 10.1002/phar.1286

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Sorafenib-induced thyroid storm; ceftaroline-induced eosinophilic pneumonia; imatinib-induced osteonecrosis of the tibia; visual and auditory hallucinations with citalopram.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2014-02

2.  Ceftaroline fosamil: a brief clinical review.

Authors:  Debbie-Ann T Shirley; Emily L Heil; J Kristie Johnson
Journal:  Infect Dis Ther       Date:  2013-08-08

3.  Eosinophilic pneumonia caused by cefepime: A case report and review.

Authors:  Bruce M Jones; E Yancey Murray; Courtney Crosby; Scott Rojas; Christopher M Bland
Journal:  IDCases       Date:  2021-05-19

4.  Ceftaroline-related acute eosinophilic pneumonia.

Authors:  Zaw Min; Rawiya Elrufay; Christian Y Cho; Subbarao Elapavaluru; Nitin Bhanot
Journal:  Lung India       Date:  2021 Jul-Aug
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.